Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150013/S034

PD-L1 IHC 22C3 pharmDx

Agilent Technologies, Inc. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONP150013/S034

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-21 for PMA supplement P150013/S034, submitted by Agilent Technologies, Inc. as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns PD-L1 IHC 22C3 pharmDx, an immunohistochemistry assay in the Pathology specialty under product code PLS. The recorded statement describes approval for a supplier's change to the manufacturing site for a device component.

This action covers only that supplier and manufacturing-site change within the existing P150013 approval; it is not a new approval of the assay as a whole. The source record does not identify the affected component, the supplier, the specific sites, or any supporting documents, and it gives no clinical or performance data. Whether the change affects labeling, analytical validation, or intended use cannot be determined from the available fields.

FDA approval order statement

approval for a supplier's change to the manufacturing sight for a device component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 21, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150013/S034
Regulatory pathway
PMA supplement
Product code
PLS
Decision code
OK30
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.

Product code
PLS
FDA device class
3

For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150013 · Original PMA

    PD-L1 IHC 22C3 PHARMDX

  2. P150013/S034 received

    Application receipt date recorded by FDA.

  3. P150013/S034 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150013

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalOct 2, 2015FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records